Helmholtz Centre for Infection Research, Braunschweig 38124, Germany.
J Hepatol. 2010 Jun;52(6):921-9. doi: 10.1016/j.jhep.2009.12.034. Epub 2010 Mar 20.
Hepatocellular carcinoma (HCC) is a deadly cancer, whose incidence is increasing worldwide. Albeit the main risk factors for HCC development have been clearly identified, such as hepatitis B and C virus infection and alcohol abuse, there is still preliminary understanding of the key drivers of this malignancy. Recent data suggest that genomic analysis of cirrhotic tissue - the pre-neoplastic carcinogenic field - may provide a read-out to identify at risk populations for cancer development. Given this contextual complexity, it is of utmost importance to characterize the molecular pathogenesis of this disease, and pinpoint the dominant pathways/drivers by integrative oncogenomic approaches and/or sophisticated experimental models. Identification of the dominant proliferative signals and key aberrations will allow for a more personalized therapy. Pathway-based approaches and functional experimental studies have aided in identifying the activation of different signaling cascades in HCC (e.g. epidermal growth factor, insulin-like growth factor, RAS, MTOR, WNT-betacatenin, etc.). However, the introduction of new high-throughput genomic technologies (e.g. microarrays, deep sequencing, etc.), and increased sophistication of computational biology (e.g. bioinformatics, biomodeling, etc.), opens the field to new strategies in oncogene and tumor suppressor discovery. These oncogenomic approaches are framed within emerging new disciplines such as systems biology, which integrates multiple inputs to explain cancer onset and progression. In addition, the consolidation of sophisticated animal models, such as mosaic cancer mouse models or the use of transposons for mutagenesis screens, have been instrumental for the identification of novel tumor drivers. We herein review some classical as well as some recent fast track approaches for oncogene discovery in HCC, and provide a comprehensive landscape of the currently known spectrum of molecular aberrations involved in hepatocarcinogenesis.
肝细胞癌(HCC)是一种致命的癌症,其发病率在全球范围内呈上升趋势。尽管已经明确确定了 HCC 发展的主要危险因素,如乙型和丙型肝炎病毒感染和酗酒,但对于这种恶性肿瘤的关键驱动因素仍知之甚少。最近的数据表明,对肝硬化组织(癌前致癌场)的基因组分析可能提供一种读出信号,以识别癌症发展的高危人群。鉴于这种复杂的背景,对这种疾病的分子发病机制进行特征描述,并通过综合肿瘤基因组学方法和/或复杂的实验模型确定优势途径/驱动因素,这一点至关重要。确定主要的增殖信号和关键异常将允许更个性化的治疗。基于途径的方法和功能实验研究有助于确定 HCC 中不同信号级联的激活(例如表皮生长因子、胰岛素样生长因子、RAS、MTOR、WNT-β-catenin 等)。然而,新的高通量基因组技术(例如微阵列、深度测序等)的引入,以及计算生物学(例如生物信息学、生物建模等)的日益复杂化,为发现致癌基因和肿瘤抑制基因开辟了新的策略。这些肿瘤基因组学方法是在系统生物学等新兴新学科框架内提出的,该学科整合了多个输入来解释癌症的发生和进展。此外,复杂的动物模型(如嵌合癌症小鼠模型或转座子用于诱变筛选)的整合对于鉴定新的肿瘤驱动因素也非常重要。本文综述了 HCC 中致癌基因发现的一些经典和最近的快速通道方法,并提供了目前已知的涉及肝癌发生的分子异常谱的全面概述。